Development and Testing of Thrombolytics in Stroke

키워드

참고문헌 (293)

1. GBD 2016 Stroke Collaborators, "Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 18, pp.439~458 (2019)
2. Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
3. Jovin TG, "Thrombectomy within 8 hours after symptom onset in ischemic stroke", N Engl J Med, 372, pp.2296~2306 (2015)
4. Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)
5. Albers GW, "Thrombectomy for stroke at 6 to 16hours with selection by perfusion imaging", N Engl J Med, 378, pp.708~718 (2018)
6. Aguiar de Sousa D, "Access to and delivery of acute ischaemic stroke treatments : a survey of national scientific societies and stroke experts in 44 European countries", Eur Stroke J, 4, pp.13~28 (2019)
7. Jong S. Kim, "tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?", 대한뇌졸중학회지, 21(2), pp.160~174 (2019), 대한뇌졸중학회[DOI]
8. Rijken DC, "Purification and partial characterization of plasminogen activator from human uterine tissue", Biochim Biophys Acta, 580, pp.140~153 (1979)
9. Rijken DC, "Fibrinolytic properties of one-chain and two-chain human extrinsic(tissue-type)plasminogen activator", J Biol Chem, 257, pp.2920~2925 (1982)
10. Angles-Cano E, "Production of monoclonal antibodies to the high fibrin-affinity, tissue-type plasminogen activator of human plasma: demonstration of its endothelial origin by immunolocalization", Blood, 66, pp.913~920 (1985)
11. Correa F, "Tissue plasminogen activator prevents white matter damage following stroke", J Exp Med, 208, pp.1229~1242 (2011)
12. Louessard M, "Tissue plasminogen activator expression is restricted to subsets of excitatory pyramidal glutamatergic neurons", Mol Neurobiol, 53, pp.5000~5012 (2016)
13. Ny T, "The structure of the human tissue-type plasminogen activator gene : correlation of intron and exon structures to functional and structural domains", Proc Natl Acad Sci U S A, 81, pp.5355~5359 (1984)
14. Lijnen HR, "Strategies for the improvement of thrombolytic agents", Thromb Haemost, 66, pp.88~110 (1991)
15. Gething MJ, "Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain", EMBO J, 7, pp.2731~2740 (1988)
16. Collen D, "Tissue-type plasminogen activator : a historical perspective and personal account", J Thromb Haemost, 2, pp.541~546 (2004)
17. Lucore CL, "Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation", Circulation, 77, pp.906~914 (1988)
18. Bakhit C, "Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes", J Biol Chem, 262, pp.8716~8720 (1987)
19. Pennica D, "Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli", Nature, 301, pp.214~221 (1983)
20. Baranes D, "Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway", Neuron, 21, pp.813~825 (1998)
21. Lee SH, "tPA regulates neurite outgrowth by phosphorylation of LRP5", 6in neural progenitor cells, 2014, pp.49, 199~215
22. Nicole O, "The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling", Nat Med, 7, pp.59~64 (2001)
23. Pang PT, "Cleavage of proBDNF by tPA", plasmin is essential for longterm hippocampal plasticity, 2004, pp.306, 487~491
24. Pawlak R, "Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior", Nat Neurosci, 6, pp.168~174 (2003)
25. Seeds NW, "Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene", Proc Natl Acad Sci U S A, 96, pp.14118~14123 (1999)
26. Su EJ, "Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke", J Thromb Haemost 2009;7Suppl, 7(Suppl 1), pp.155~158 (2009)
27. Sila CA, "Therapy for acute ischemic stroke : the door opens : interpreting the NINDS rt-PA stroke study", Cleve Clin J Med, 63, pp.77~79 (1996)
28. Emberson J, "Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials", Lancet, 384, pp.1929~1935 (2014)
29. Suzuki S, "Thrombolytic properties of a novel modified human tissue-type plasminogen activator(E6010) : a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi", J Cardiovasc Pharmacol, 17, pp.738~746 (1991)
30. den Heijer P, "Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase", Circulation, 98, pp.2117~2125 (1998)
31. Ishikawa A, "Single and repeated intravenous toxicity studies of pamiteplase(genetical recombination)in rats and monkeys", J Toxicol Sci, 22, pp.117~133 (1997)
32. Agnelli G, "Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life(K2tu-PA : CGP 42935)", Thromb Haemost, 70, pp.294~300 (1993)
33. Narita M, "Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator(t-PA)in vivo", J Clin Invest, 96, pp.1164~1168 (1995)
34. Kuiper J, "Interaction of mutants of tissue-type plasminogen activator with liver cells : effect of domain deletions", Biochem J, 313, pp.775~780 (1996)
35. Rathore YS, "First structural model of full-length human tissue-plasminogen activator : a SAXS data-based modeling study", J Phys Chem B, 116, pp.496~502 (2012)
36. Mican J, "Structural biology and protein engineering of thrombolytics", Comput Struct Biotechnol J, 17, pp.917~938 (2019)
37. Keyt BA, "A faster-acting and more potent form of tissue plasminogen activator", Proc Natl Acad Sci U S A, 91, pp.3670~3674 (1994)
38. Campbell BC, "Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study", Int J Stroke, 13, pp.328~334 (2018)
39. Macfarlane RG, "Fibrinolytic activity of normal urine", Nature, 159, pp.779~ (1947)
40. Gibson PR, "Cell associated urokinase activity and colonic epithelial cells in health and disease", Gut, 32, pp.191~195 (1991)
41. Helenius MA, "Amplification of urokinase gene in prostate cancer", Cancer Res, 61, pp.5340~5344 (2001)
42. Kusch A, "Monocyte-expressed urokinase regulates human vascular smooth muscle cell migration in a coculture model", Biol Chem, 383, pp.217~221 (2002)
43. Medcalf RL, "Human synovial fibroblasts produce urokinase-type plasminogen activator", Arthritis Rheum, 29, pp.1397~1401 (1986)
44. Sidenius N, "The urokinase plasminogen activator system in cancer : recent advances and implication for prognosis and therapy", Cancer Metastasis Rev, 22, pp.205~222 (2003)
45. Roychoudhury PK, "Synthesis, regulation and production of urokinase using mammalian cell culture: a comprehensive review", Biotechnol Adv, 24, pp.514~528 (2006)
46. Collen D, "Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and", or duplication of structural, Thromb Haemost, pp.1991, 65[DOI]
47. Kadir RRA, "Urokinase plasminogen activator : a potential thrombolytic agent for ischaemic stroke", Cell Mol Neurobiol, 40, pp.347~355 (2020)
48. Bell WR, "The urokinase-streptokinase pulmonary embolism trial(phase II)results", Circulation, 50, pp.1070~1071 (1974)
49. Spiecker M, "Thrombolysis with saruplase versus streptokinase in acute myocardial infarction : five-year results of the PRIMI trial", Am Heart J, 138, pp.518~524 (1999)
50. Bär FW, "Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction", Am J Cardiol, 79, pp.727~732 (1997)
51. Tillett WS, "The fibrinolytic activity of hemolytic streptococci", J Exp Med, 58, pp.485~502 (1933)
52. Sun H, "Plasminogen is a critical host pathogenicity factor for group A streptococcal infection", Science, 305, pp.1283~1286 (2004)
53. Lack CH, "Staphylokinase; an activator of plasma protease", Nature, 161, pp.559~ (1948)
54. Collen D, "Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent", Nat Med, 4, pp.279~284 (1998)
55. Sakharov DV, "Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin", J Biol Chem, 271, pp.27912~27918 (1996)
56. Armstrong PW, "Collaborative angiographic patency trial of recombinant staphylokinase(CAPTORS II)", Am Heart J, 146, pp.484~488 (2003)
57. Armstrong PW, "Collaborative angiographic patency trial of recombinant staphylokinase(CAPTORS)", Am Heart J, 139, pp.820~823 (2000)
58. Cartwright T, "The plasminogen activator of vampire bat saliva", Blood, 43, pp.317~326 (1974)
59. Krätzschmar J, "The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus : cloning and expression", Gene, 105, pp.229~237 (1991)
60. Bringmann P, "Structural features mediating fibrin selectivity of vampire bat plasminogen activators", J Biol Chem, 270, pp.25596~25603 (1995)
61. Kazemali M, "Design of a novel chimeric tissue plasminogen activator with favorable vampire bat plasminogen activator properties", Enzyme Microb Technol, 67, pp.82~86 (2014)
62. Saadatirad A, "Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties", Mol Biotechnol, 56, pp.1143~1150 (2014)
63. Hacke W, "The desmoteplase in acute ischemic stroke trial(DIAS) : a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase", Stroke, 36, pp.66~73 (2005)
64. Furlan AJ, "Dose escalation of desmoteplase for acute ischemic stroke(DEDAS) : evidence of safety and efficacy 3 to 9hours after stroke onset", Stroke, 37, pp.1227~1231 (2006)
65. Albers GW, "Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial", Lancet Neurol, 14, pp.575~584 (2015)
66. Van de Werf FJ, "The ideal fibrinolytic : can drug design improve clinical results", Eur Heart J, 20, pp.1452~1458 (1999)
67. Tennant SN, "Intracoronary thrombolysis in patients with acute myocardial infarction : comparison of the efficacy of urokinase with streptokinase", Circulation, 69, pp.756~760 (1984)
68. Marini C, "Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism : a randomized clinical trial", Respiration, 54, pp.162~173 (1988)
69. Van Hulle F, "Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters : a retrospective cohort study", J Vasc Access, 20, pp.60~69 (2019)
70. Hoylaerts M, "Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin", J Biol Chem, 257, pp.2912~2919 (1982)
71. Urano T, "Regulation of plasminogen activation on cell surfaces and fibrin", J Thromb Haemost, 16, pp.1487~1497 (2018)
72. Collen D, "The tissue-type plasminogen activator story", Arterioscler Thromb Vasc Biol, 29, pp.1151~1155 (2009)
73. Campbell BCV, "Tenecteplase versus alteplase before thrombectomy for ischemic stroke", N Engl J Med, 378, pp.1573~1582 (2018)
74. Bhatia R, "Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke : real-world experience and a call for action", Stroke, 41, pp.2254~2258 (2010)
75. Bivard A, "Tenecteplase in ischemic stroke offers improved recanalization : analysis of 2 trials", Neurology, 89, pp.62~67 (2017)
76. Yaghi S, "Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke : a scientific statement for healthcare professionals from the American Heart Association", American Stroke Association, 2017, pp.48, e343~e361
77. National Institute of Neurological Disorders, "Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
78. Mair G, "Arterial obstruction on computed tomographic or magnetic resonance angiography and response to intravenous thrombolytics in ischemic stroke", Stroke, 48, pp.353~360 (2017)
79. Riedel CH, "The importance of size : successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length", Stroke, 42, pp.1775~1777 (2011)
80. Menon BK, "Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke", JAMA, 320, pp.1017~1026 (2018)
81. Zhang Y, "Streptococcus uberis plasminogen activator(SUPA)activates human plasminogen through novel species-specific and fibrin-targeted mechanisms", J Biol Chem, 287, pp.19171~19176 (2012)
82. Hu Y, "Purification and characterization of a novel, highly potent fibrinolytic enzyme from Bacillus subtilis DC27 screened from Douchi, a traditional Chinese fermented soybean food", Sci Rep, 9, pp.9235~ (2019)
83. Khursade PS, "Stenotrophomonas maltophilia Gd2 : a potential and novel isolate for fibrinolytic enzyme production", Saudi J Biol Sci, 26, pp.1567~1575 (2019)
84. Chen H, "Nattokinase : a promising alternative in prevention and treatment of cardiovascular diseases", Biomark Insights, 13, pp.1~ (2018)
85. Silva PEDCE, "In vitro thrombolytic activity of a purified fibrinolytic enzyme from Chlorella vulgaris", J Chromatogr B Analyt Technol Biomed Life Sci, 1092, pp.524~529 (2018)
86. He J, "Identification and characterization of Harobin, a novel fibrino(geno)lytic serine protease from a sea snake (Lapemis hardwickii)", FEBS Lett, 581, pp.2965~2973 (2007)
87. Li Z, "Engineering of Harobin for enhanced fibrinolytic activity obtained by random and site-directed mutagenesis", Protein Expr Purif, 129, pp.162~172 (2017)
88. 김혜진, "A Novel Thrombolytic and Anticoagulant Serine Protease from Polychaeta, Diopatra sugokai", Journal of Microbiology and Biotechnology, 28(2), pp.275~283 (2018), 한국미생물·생명공학회
89. Vanacek P, "Exploration of enzyme diversity by integrating bioinformatics with expression analysis and biochemical characterization", ACS Catal, 8, pp.2402~2412 (2018)
90. Suzuki E, "Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys", Pharmacol Res Perspect, 6, pp.e00448~ (2018)
91. van Zonneveld AJ, "Autonomous functions of structural domains on human tissue-type plasminogen activator", Proc Natl Acad Sci U S A, 83, pp.4670~4674 (1986)
92. Medcalf RL, "Fibrinolysis : from blood to the brain", J Thromb Haemost, 15, pp.2089~2098 (2017)
93. Niego B, "t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes", Blood, 119, pp.4752~4761 (2012)
94. Thiebaut AM, "The role of plasminogen activators in stroke treatment : fibrinolysis and beyond", Lancet Neurol, 17, pp.1121~1132 (2018)
95. Horn IR, "Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator", Thromb Haemost, 80, pp.822~828 (1998)
96. Cole ES, "In vivo clearance of tissue plasminogen activator : the complex role of sites of glycosylation and level of sialylation", Fibrinolysis, 7, pp.15~22 (1993)
97. Mohammadi E, "Reteplase: structure, function, and production", Adv Biomed Res, 8, pp.19~ (2019)
98. Maheshwari N, "Amino-terminal fusion of epidermal growth factor 4, 5, 6 domains of human thrombomodulin on streptokinase confers anti-reocclusion characteristics along with plasmin-mediated clot specificity", PLoS One, 11, pp.e0150315~ (2016)
99. Taheri MN, "Engineering, expression and purification of a chimeric fibrin-specific streptokinase", Protein Expr Purif, 128, pp.14~21 (2016)
100. He J, "Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini", Biotechnol Appl Biochem, 50, pp.17~23 (2008)
101. Szemraj J, "A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity: a staphylokinase variant. I. In vitro study", J Thromb Haemost, 3, pp.2156~2165 (2005)
102. Chiou JF, "Staphylokinase-annexin XI chimera exhibited efficient in vitro thrombolytic activities", Biosci Biotechnol Biochem, 71, pp.1122~1129 (2007)
103. Faraji H, "Comparison of expression optimization of new derivative of staphylokinase (SAK-2RGDTTI) with the rSAK", Biotechnol Prog, 35, pp.e2819~ (2019)
104. Wu SC, "A fast-acting, modular-structured staphylokinase fusion with kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy", J Biol Chem, 278, pp.18199~18206 (2003)
105. Raigani M, "Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator(mt-PA)in rats", Sci Rep, 7, pp.43028~ (2017)
106. Davami F, "Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments", J Biomed Biotechnol, 2010, pp.108159~ (2010)
107. Bonnard T, "Novel thrombolytic drug based on thrombin cleavable microplasminogen coupled to a single-chain antibody specific for activated GPIIb", IIIa, 2017, pp.6, e004535~
108. Wu XC, "Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis : streptokinase with longer functional half-life", Appl Environ Microbiol, 64, pp.824~829 (1998)
109. Babbal A, "Engineering of deglycosylated and plasmin resistant variants of recombinant streptokinase in Pichia pastoris", Appl Microbiol Biotechnol, 102, pp.10561~10577 (2018)
110. Sawhney P, "PEGylation of truncated streptokinase leads to formulation of a useful drug with ameliorated attributes", PLoS One, 11, pp.e0155831~ (2016)
111. Xu Y, "Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase", Microb Cell Fact, 16, pp.197~ (2017)
112. Collen D, "Engineered staphylokinase variants with reduced immunogenicity", Fibrinolysis Proteolysis, 12(Suppl 2), pp.59~65 (1998)
113. Thomas GR, "A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding", Stroke, 25, pp.2072~2078 (1994)
114. Armstead WM, "tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury", J Neurotrauma, 29, pp.1794~1802 (2012)
115. Goulay R, "Optimized tPA : a non-neurotoxic fibrinolytic agent for the drainage of intracerebral hemorrhages", J Cereb Blood Flow Metab, 38, pp.1180~1189 (2018)
116. Gurewich V, "Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator", J Thromb Haemost, 4, pp.1559~1565 (2006)
117. Koudelka S, "Liposomal nanocarriers for plasminogen activators", J Control Release, 227, pp.45~57 (2016)
118. Bruch GE, "Liposomes for drug delivery in stroke", Brain Res Bull, 152, pp.246~256 (2019)
119. Kim JY, "The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator", Biomaterials, 30, pp.5751~5756 (2009)
120. Al-Ahmady ZS, "Selective liposomal transport through blood brain barrier disruption in ischemic stroke reveals two distinct therapeutic opportunities", ACS Nano, 13, pp.12470~12486 (2019)
121. Partoazar A, "Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia", reperfusion in rat, 2017, pp.31, 185~193
122. Tiebosch IA, "Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats", J Neurochem, 123, pp.65~74 (2012)
123. Absar S, "Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy", J Thromb Haemost, 13, pp.1545~1556 (2015)
124. Zhang N, "Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis", Acta Biomater, 70, pp.227~236 (2018)
125. Laing ST, "Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model-brief report", Arterioscler Thromb Vasc Biol, 31, pp.1357~1359 (2011)
126. Korin N, "Targeted drug delivery to flow-obstructed blood vessels using mechanically activated nanotherapeutics", JAMA Neurol, 72, pp.119~122 (2015)
127. Saxena V, "Temperature-sensitive liposome-mediated delivery of thrombolytic agents", Int J Hyperthermia, 31, pp.67~73 (2015)
128. Xu J, "Engineered nanoplatelets for targeted delivery of plasminogen activators to reverse thrombus in multiple mouse thrombosis models", Adv Mater, 32, pp.e1905145~ (2020)
129. Chen K, "Intrinsic biotaxi solution based on blood cell membrane cloaking enables fullerenol thrombolysis in vivo", ACS Appl Mater Interfaces, 12, pp.14958~14970 (2020)
130. Wang X, "Crystal structure of the catalytic domain of human plasmin complexed with streptokinase", Science, 281, pp.1662~1665 (1998)
131. Rehan M, "Penta-l-lysine potentiates fibrin-independent activity of human tissue plasminogen activator", J Phys Chem B, 119, pp.13271~13277 (2015)
132. Ghaheh HS, "Improving the solubility, activity, and stability of reteplase using in silico design of new variants", Research in pharmaceutical sciences, 14, pp.359~368 (2019)
133. Krishnamurthy A, "Methods available to assess therapeutic potential of fibrinolytic enzymes of microbial origin : a review", J Anal Sci Technol, 9, pp.10~ (2018)
134. Kotb E, "Activity assessment of microbial fibrinolytic enzymes", Appl Microbiol Biotechnol, 97, pp.6647~6665 (2013)
135. Millar WT, "A highly sensitive solid phase assay for plasminogen activators using 125I-fibrinogen", Thromb Res, 13, pp.389~395 (1978)
136. Millar WT, "The comparison of solid phase and fibrin plate methods for the measurement of plasminogen activators", Thromb Res, 30, pp.431~439 (1983)
137. Hume M, "Radioactive(I125)human plasma clots for assay of thrombolytic activity", J Lab Clin Med, 63, pp.699~702 (1964)
138. Moroz LA, "A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin", Blood, 46, pp.543~553 (1975)
139. Loskutoff DJ, "Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells", J Clin Invest, 64, pp.329~332 (1979)
140. Roche PC, "A rapid and highly sensitive solid-phase radioassay for plasminogen activators", Thromb Res, 31, pp.269~277 (1983)
141. Gidron E, "A rapid screening test for reduced fibrinolytic activity of plasma : streptokinase activated lysis time", J Clin Pathol, 31, pp.54~57 (1978)
142. Patchett SE, "Clot lysis by gastric juice : an in vitro study", Gut, 30, pp.1704~1707 (1989)
143. Goldenberg NA, "A new global assay of coagulation and fibrinolysis", J Thromb Res, 116, pp.345~356 (2005)
144. Astrup T, "The fibrin plate method for estimating fibrinolytic activity", Arch Biochem Biophys, 40, pp.346~351 (1952)
145. Jespersen J, "A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision", Haemostasis, 13, pp.301~315 (1983)
146. Marsh NA, "The rapid fibrin plate : a method for plasminogen activator assay", J Thromb Haemost, 38, pp.545~551 (1977)
147. Lassen M, "Heat denaturation of plasminogen in the fibrin plate method", Acta Physiol Scand, 27, pp.371~376 (1953)
148. Barta G, "Dyed fibrin plate assay of fibrinolysis", Can J Physiol Pharmacol, 44, pp.233~240 (1966)
149. Fossum S, "Urokinase and non-urokinase fibrinolytic activity in protease-inhibitor-deprived plasma, assayed by a fibrin micro-plate method", Immunopharmacology, 32, pp.119~121 (1996)
150. Sherry S, "Activity of plasmin and streptokinase-activator on substituted arginine and lysine esters", Thromb Diath Haemorrh, 16, pp.18~31 (1966)
151. Niinobe M, "A sensitive colorimetric assay for various proteases using naphthyl ester derivatives as substrates", J Biochem, 87, pp.779~783 (1980)
152. Barlow GH, "Plasma urokinase levels measured by chromogenic assay after infusions of tissue culture or urinary source material", Thromb Res, 18, pp.431~437 (1980)
153. Kulseth MA, "A highly sensitive chromogenic microplate assay for quantification of rat and human plasminogen", Anal Biochem, 210, pp.314~317 (1993)
154. Nieuwenhuizen W, "Fluorogenic substrates for sensitive and differential estimation of urokinase and tissue plasminogen activator", Haemostasis, 7, pp.146~149 (1978)
155. Zimmerman M, "Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells : kinetics and inhibitor profiles", Proc Natl Acad Sci U S A, 75, pp.750~753 (1978)
156. Mander P, "A low molecular weight chymotrypsin-like novel fibrinolytic enzyme from Streptomyces sp. CS624", Process Biochem, 46, pp.1449~1455 (2011)
157. Salazar AM, "A comparative analysis of the clotting and fibrinolytic activities of the snake venom(Bothrops atrox)from different geographical areas in Venezuela", Thromb Res, 120, pp.95~104 (2007)
158. Stewart RJ, "Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator", J Biol Chem, 275, pp.10112~10120 (2000)
159. Radcliffe R, "Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots : a possible additional role for plasminogen activator", Arch Biochem Biophys, 211, pp.750~761 (1981)
160. Longstaff C, "A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units", Thromb Haemost, 2, pp.1416~1421 (2004)
161. Stewart RJ, "Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of d-Dimer noncovalently linked to fragment E", J Biol Chem, 273, pp.18292~18299 (1998)
162. Hawkey CM, "A standard clot method for the assay of plasminogen activators, anti-activators, and plasmin", J Clin Pathol, 17, pp.175~181 (1964)
163. Somerville DA, "A technique for demonstrating fibrinolysis by cutaneous bacteria", J Clin Pathol, 25, pp.740~741 (1972)
164. Chakrabarti R, "The ‘fibrinolytic potential’ as a simple measure of spontaneous fibrinolysis", J Clin Pathol, 15, pp.228~230 (1962)
165. Blix S, "The effectiveness of activators in clot lysis, with special reference to fibrinolytic therapy: a new method for determination of preformed clot lysis", Acta Med Scand Suppl, 386, pp.1~24 (1962)
166. Howell M, "A method for assessing clot lysis", J Clin Pathol, 17, pp.310~312 (1964)
167. Prasad S, "Development of an in vitro model to study clot lysis activity of thrombolytic drugs", Thromb J, 4, pp.14~ (2006)
168. Narasimhan MK, "Fibrinolytic enzyme production by newly isolated Bacillus cereus SRM001 with enhanced in-vitro blood clot lysis potential", J Gen Appl Microbiol, 61, pp.157~164 (2015)
169. Smith AA, "A new euglobulin clot lysis assay for global fibrinolysis", J Thromb Res, 112, pp.329~337 (2003)
170. He S, "A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results", Thromb Res, 96, pp.145~156 (1999)
171. Ilich A, "Development and application of global assays of hyper-and hypofibrinolysis", Res Pract Thromb Haemost, 4, pp.46~53 (2020)
172. Zamanlu M, "Spectrophotometric analysis of thrombolytic activity : SATA assay", Bioimpacts, 8, pp.31~38 (2018)
173. Bonnard T, "Development and validation of a high throughput whole blood thrombolysis plate assay", Sci Rep, 7, pp.2346~ (2017)
174. Donahue SM, "Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis", J Vet Emerg Crit Care, 15, pp.9~16 (2005)
175. Bolliger D, "Principles and practice of thromboelastography in clinical coagulation management and transfusion practice", Transfus Med Rev, 26, pp.1~13 (2012)
176. Fan NK, "Experimental and imaging techniques for examining fibrin clot structures in normal and diseased states", J Vis Exp, 98, pp.e52019~ (2015)
177. Kim DE, "Combined near-infrared fluorescent imaging and micro-computed tomography for directly visualizing cerebral thromboemboli", J Vis Exp (2016)
178. Fatemeh Davami, "A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on In Silico experiments", BMB Reports, 44(1), pp.34~39 (2011), 생화학분자생물학회
179. Hekman CM, "Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator", Arch Biochem Biophys, 262, pp.199~210 (1988)
180. Chmielewska J, "Evidence for a rapid inhibitor to tissue plasminogen activator in plasma", Thromb Res, 31, pp.427~436 (1983)
181. Franke AE, "Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1", Biochim Biophys Acta, 1037, pp.16~23 (1990)
182. Wind T, "Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 : implications for antibody-mediated PAI-1-neutralization and vitronectin-binding", Eur J Biochem, 268, pp.1095~1106 (2001)
183. Yakovlev S, "Conversion of fibrinogen to fibrin : mechanism of exposure of tPA-and plasminogen-binding sites", Biochemistry, 39, pp.15730~15741 (2000)
184. Tsurupa G, "Identification and characterization of novel tPA-and plasminogen-binding sites within fibrin(ogen)alpha C-domains", Biochemistry, 40, pp.801~808 (2001)
185. Kim PY, "A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue plasminogen activator", J Biol Chem, 287, pp.4652~4661 (2012)
186. Tsurupa G, "Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites", Ann N Y Acad Sci, 936, pp.328~330 (2001)
187. de Munk GA, "Binding of tissue-type plasminogen activator to lysine, lysine analogues, and fibrin fragments", Biochemistry, 28, pp.7318~7325 (1989)
188. Jiao J, "Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding", Enzymology, 1546, pp.399~405 (2001)
189. Higgins DL, "Interaction of one-chain and twochain tissue plasminogen activator with intact and plasmin-degraded fibrin", Biochemistry, 26, pp.7786~7791 (1987)
190. Verheijen JH, "Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin", EMBO J, 5, pp.3525~3530 (1986)
191. Xu Z, "Conservation of critical functional domains in murine plasminogen activator inhibitor-1", J Biol Chem, 279, pp.17914~17920 (2004)
192. Andersen OM, "Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein", Biochem J, 357, pp.289~296 (2001)
193. Sánchez MC, "Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein(LRP)", Arch Biochem Biophys, 389, pp.218~222 (2001)
194. Dolmer K, "Quantitative dissection of the binding contributions of ligand lysines of the receptor-associated protein(RAP)to the low density lipoprotein receptor-related protein(LRP1)", J Biol Chem, 288, pp.24081~24090 (2013)
195. Jensen JK, "Receptor-associated protein(RAP)has two high-affinity binding sites for the low-density lipoprotein receptor-related protein(LRP) : consequences for the chaperone functions of RAP", Biochem J, 421, pp.273~282 (2009)
196. Asahi M, "Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke", J Cereb Blood Flow Metab, 23, pp.895~899 (2003)
197. Esmaeeli-Nadimi A, "Opening the window : ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model", Eur J Pharmacol, 764, pp.55~62 (2015)
198. Hao CH, "Thrombolysis with rhPro-UK 3 to 6 hours after embolic stroke in rat", Neurol Res, 41, pp.1034~1042 (2019)
199. Ishrat T, "Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: a randomized, blinded preclinical trial in a rat model of thromboembolic stroke", J Cereb Blood Flow Metab, 39, pp.1635~1647 (2019)
200. Jin R, "Taurine reduces tPA(tissue-type plasminogen activator)-induced hemorrhage and microvascular thrombosis after embolic stroke in rat", Stroke, 49, pp.1708~1718 (2018)
201. Jin R, "Embolic middle cerebral artery occlusion(MCAO)for ischemic stroke with homologous blood clots in rats", J Vis Exp, 91, pp.51956~ (2014)
202. Kudo M, "An animal model of cerebral infarction. Homologous blood clot emboli in rats", Stroke, 13, pp.505~508 (1982)
203. Lee KY, "Neuroprotective effect of asiatic acid in rat model of focal embolic stroke", Biol Pharm Bull, 37, pp.1397~1401 (2014)
204. Lehmann J, "Inflammatory cell recruitment after experimental thromboembolic stroke in rats", Neuroscience, 279, pp.139~154 (2014)
205. Ren M, "Embolic middle cerebral artery occlusion model using thrombin and fibrinogen composed clots in rat", J Neurosci Methods, 211, pp.296~304 (2012)
206. Shimamura N, "A model of rat embolic cerebral infarction with a quantifiable, autologous arterial blood clot", Transl Stroke Res, 4, pp.564~570 (2013)
207. Si Z, "Effects of thrombolysis within 6 hours on acute cerebral infarction in an improved rat embolic middle cerebral artery occlusion model for ischaemic stroke", J Cell Mol Med, 23, pp.2468~2474 (2019)
208. Takano K, "Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging", Neurology, 50, pp.870~875 (1998)
209. Zhang L, "Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats", J Cereb Blood Flow Metab, 29, pp.1816~1824 (2009)
210. Zhang L, "Demonstration of therapeutic window of cerebrolysin in embolic stroke: a prospective, randomized, blinded, and placebo-controlled study", Int J Stroke, 12, pp.628~635 (2017)
211. Zhang L, "Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke", Stroke, 44, pp.1965~1972 (2013)
212. Zhang L, "Focal embolic cerebral ischemia in the rat", Nat Protoc, 10, pp.539~547 (2015)
213. Chen S, "Early abrogation of gelatinase activity extends the time window for tPA thrombolysis after embolic focal cerebral ischemia in mice", eNeuro, 5 (2018)[DOI]
214. Huang L, "Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke", Biochem Biophys Res Commun, 516, pp.565~570 (2019)
215. Kanazawa M, "Multiple therapeutic effects of progranulin on experimental acute ischaemic stroke", Brain, 138, pp.1932~1948 (2015)
216. Kim DE, "Direct thrombus imaging as a means to control the variability of mouse embolic infarct models : the role of optical molecular imaging", Stroke, 42, pp.3566~3573 (2011)
217. Kim JY, "Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles", Theranostics, 5, pp.1098~1114 (2015)
218. Sladojevic N, "Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets", Cardiovasc Res, 113, pp.1307~1317 (2017)
219. Zhu YQ, "Evaluation of neurovascular function in mouse cortex using multispectral optical imaging after ischemic stroke", Zhonghua Yi Xue Za Zhi, 99, pp.2943~2946 (2019)
220. Culp WC, "Dodecafluoropentane emulsion decreases infarct volume in a rabbit ischemic stroke model", J Vasc Interv Radiol, 23, pp.116~121 (2012)
221. Jahan R, "Selective middle cerebral artery occlusion in the rabbit : technique and characterization with pathologic findings and multimodal MRI", J Neurosci Methods, 313, pp.6~12 (2019)
222. Lapchak PA, "Microplasmin : a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits", Stroke, 33, pp.2279~2284 (2002)
223. benzene-1,3-disulfonate N-oxide (generic NXY-059)on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator, "Stroke", 2002, 1665~1670
224. benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator, "Stroke", 2002, 1411~1415
225. Liu S, "Simple quantitative measurement based on DWI to objectively judge DWI-FLAIR mismatch in a canine stroke model", Diagn Interv Radiol, 21, pp.348~354 (2015)
226. Xu XQ, "Comparative study of the relative signal intensity on DWI, FLAIR, and T2 images in identifying the onset time of stroke in an embolic canine model", Neurol Sci, 35, pp.1059~1065 (2014)
227. Lee IJ, "Zebrafish model of photochemical thrombosis for translational research and thrombolytic screening in vivo", J Biophotonics, 10, pp.494~502 (2017)
228. Kito G, "Experimental thromboembolic stroke in cynomolgus monkey", J Neurosci Methods, 105, pp.45~53 (2001)
229. Kuge Y, "Serial changes in cerebral blood flow and flow-metabolism uncoupling in primates with acute thromboembolic stroke", J Cereb Blood Flow Metab, 21, pp.202~210 (2001)
230. Ansar S, "Characterization of a new model of thromboembolic stroke in C57black", 6J mice, 2014, pp.5, 526~533
231. Zhang Z, "A new rat model of thrombotic focal cerebral ischemia", J Cereb Blood Flow Metab, 17, pp.123~135 (1997)
232. Orset C, "Mouse model of in situ thromboembolic stroke and reperfusion", Stroke, 38, pp.2771~2778 (2007)
233. Beech JS, "Further characterisation of a thromboembolic model of stroke in the rat", Brain Res, 895, pp.18~24 (2001)
234. Atochin DN, "Mouse model of microembolic stroke and reperfusion", Stroke, 35, pp.2177~2182 (2004)
235. Agren A, "In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography", Blood Transfus, 12, pp.491~496 (2014)
236. Zhang RL, "A rat model of focal embolic cerebral ischemia", Brain Res, 766, pp.83~92 (1997)
237. Kim DE, "Quantitative imaging of cerebral thromboemboli in vivo : the effects of tissue-type plasminogen activator", Stroke, 48, pp.1376~1385 (2017)
238. Chen Y, "A novel mouse model of thromboembolic stroke", J Neurosci Methods, 256, pp.203~211 (2015)
239. Smith WS, "Safety and efficacy of mechanical embolectomy in acute ischemic stroke : results of the MERCI trial", Stroke, 36, pp.1432~1438 (2005)
240. Mehta BP, "Should clot composition affect choice of endovascular therapy", Neurology, 79, pp.S63~67 (2012)
241. Gauberti M, "Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates", J Thromb Haemost, 12, pp.409~414 (2014)
242. Orset C, "Efficacy of alteplase in a mouse model of acute ischemic stroke : a retrospective pooled analysis", Stroke, 47, pp.1312~1318 (2016)
243. Tseng MT, "Transendothelial migration of ferric ion in FeCl3 injured murine common carotid artery", Thromb Res, 118, pp.275~280 (2006)
244. Ciciliano JC, "Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach", Blood, 126, pp.817~824 (2015)
245. Kurz KD, "Rat model of arterial thrombosis induced by ferric chloride", Thromb Res, 60, pp.269~280 (1990)
246. Karatas H, "Thrombotic distal middle cerebral artery occlusion produced by topical FeCl(3)application : a novel model suitable for intravital microscopy and thrombolysis studies", J Cereb Blood Flow Metab, 31, pp.1452~1460 (2011)
247. Kim DE, "Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles", Ann Neurol, 73, pp.617~625 (2013)
248. Dietrich WD, "Photochemically induced cortical infarction in the rat. 1. Time course of hemodynamic consequences", J Cereb Blood Flow Metab, 6, pp.184~194 (1986)
249. Hilger T, "Characterization of a novel chronic photothrombotic ring stroke model in rats by magnetic resonance imaging, biochemical imaging, and histology", J Cereb Blood Flow Metab, 24, pp.789~797 (2004)
250. Hu X, "Progressive and reproducible focal cortical ischemia with or without late spontaneous reperfusion generated by a ring-shaped, laser-driven photothrombotic lesion in rats", Brain Res Brain Res Protoc, 7, pp.76~85 (2001)
251. Kim HS, "A rat model of photothrombotic capsular infarct with a marked motor deficit: a behavioral, histologic, and microPET study", J Cereb Blood Flow Metab, 34, pp.683~689 (2014)
252. Kleinschnitz C, "Blocking of platelets or intrinsic coagulation pathway-driven thrombosis does not prevent cerebral infarctions induced by photothrombosis", Stroke, 39, pp.1262~1268 (2008)
253. Kuroiwa T, "Development of a rat model of photothrombotic ischemia and infarction within the caudoputamen", Stroke, 40, pp.248~253 (2009)
254. Lee VM, "Evolution of photochemically induced focal cerebral ischemia in the rat : magnetic resonance imaging and histology", Stroke, 27, pp.2110~2118 (1996)
255. Lu H, "Induction and imaging of photothrombotic stroke in conscious and freely moving rats", J Biomed Opt, 19, pp.96013~ (2014)
256. Provenzale JM, "Assessment of the patient with hyperacute stroke : imaging and therapy", Radiology, 229, pp.347~359 (2003)
257. Qian C, "Precise characterization of the penumbra revealed by MRI : a modified photothrombotic stroke model study", PLoS One, 11, pp.e0153756~ (2016)
258. Watson BD, "Induction of reproducible brain infarction by photochemically initiated thrombosis", Ann Neurol, 17, pp.497~504 (1985)
259. Schroeter M, "Non-invasive induction of focal cerebral ischemia in mice by photothrombosis of cortical microvessels : characterization of inflammatory responses", J Neurosci Methods, 117, pp.43~49 (2002)
260. Kleinschnitz C, "In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging", J Cereb Blood Flow Metab, 23, pp.1356~1361 (2003)
261. Jander S, "Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia", J Neuroimmunol, 109, pp.181~187 (2000)
262. Jolkkonen J, "Subacute hemorrhage and resolution of edema in Rose Bengal stroke model in rats coincides with improved sensorimotor functions", Neurosci Lett, 428, pp.99~102 (2007)
263. Moon SK, "Both compensation and recovery of skilled reaching following small photothrombotic stroke to motor cortex in the rat", Exp Neurol, 218, pp.145~153 (2009)
264. Pevsner PH, "A photothrombotic model of small early ischemic infarcts in the rat brain with histologic and MRI correlation", J Pharmacol Toxicol Methods, 45, pp.227~233 (2001)
265. Pierpaoli C, "Histopathologic correlates of abnormal water diffusion in cerebral ischemia : diffusion-weighted MR imaging and light and electron microscopic study", Radiology, 189, pp.439~448 (1993)
266. Schroeter M, "Dynamic changes of magnetic resonance imaging abnormalities in relation to inflammation and glial responses after photothrombotic cerebral infarction in the rat brain", Acta Neuropathol, 101, pp.114~122 (2001)
267. van Bruggen N, "T2-and diffusion-weighted magnetic resonance imaging of a focal ischemic lesion in rat brain", Stroke, 23, pp.576~582 (1992)
268. Harrison TC, "Displacement of sensory maps and disorganization of motor cortex after targeted stroke in mice", Stroke, 44, pp.2300~2306 (2013)
269. Shih AY, "The smallest stroke : occlusion of one penetrating vessel leads to infarction and a cognitive deficit", Nat Neurosci, 16, pp.55~63 (2013)
270. Sun YY, "A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment", Blood Adv, 4, pp.1222~1231 (2020)
271. Miao P, "Laser speckle contrast imaging of cerebral blood flow in freely moving animals", J Biomed Opt, 16, pp.090502~ (2011)
272. ) : a randomised controlled trial, "Lancet", 2012, 2352~2363
273. Coutts SB, "Tenecteplase for the treatment of acute ischemic stroke : a review of completed and ongoing randomized controlled trials", Int J Stroke, 13, pp.885~892 (2018)
274. Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke", N Engl J Med, 366, pp.1099~1107 (2012)
275. Logallo N, "Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial", Lancet Neurol, 16, pp.781~788 (2017)
276. Hacke W, "Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study", Lancet Neurol, 8, pp.141~150 (2009)
277. von Kummer R, "Desmoteplase 3 to 9 hours after major artery occlusion stroke : the DIAS-4 trial(efficacy and safety study of desmoteplase to treat acute ischemic stroke)", Stroke, 47, pp.2880~2887 (2016)
278. Hill MD, "Tenecteplase knocking on the door", Stroke, 49, pp.2276~2277 (2018)
279. Huang X, "Tenecteplase versus alteplase in stroke thrombolysis : an individual patient data meta-analysis of randomized controlled trials", Int J Stroke, 11, pp.534~543 (2016)
280. Burgos AM, "Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke : meta-analysis of 5 randomized trials", Stroke, 50, pp.2156~2162 (2019)
281. Alexandrov AV, "Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke", N Engl J Med, 351, pp.2170~2178 (2004)
282. Salman-Kesner N, "In-vitro assessment of the thrombolytic efficacy of therapeutic ultrasound", Thromb Res, 178, pp.63~68 (2019)
283. Papadopoulos N, "Review of protocols used in ultrasound thrombolysis", J Stroke Cerebrovasc Dis, 26, pp.2447~2469 (2017)
284. Bader KB, "Sonothrombolysis", Adv Exp Med Biol, 880, pp.339~362 (2016)
285. Wang Z, "An in vitro assay for sonothrombolysis based on the spectrophotometric measurement of clot thickness", J Ultrasound Med, 36, pp.681~698 (2017)
286. Amar DN, "Endothelial cell activation in an embolic ischemia-reperfusion injury microfluidic model", Micromachines(Basel), 10, pp.857~ (2019)
287. Parimalam SS, "Lab-on-a-chip for the development of pro-", anti-angiogenic nanomedicines to treat brain diseases, 2019, pp.20, 6126~
288. Andrzejewska A, "Single-cell, high-throughput analysis of cell docking to vessel wall", J Cereb Blood Flow Metab, 39, pp.2308~2320 (2019)
289. Griffin MT, "Shear-induced platelet aggregation : 3D-grayscale microfluidics for repeatable and localized occlusive thrombosis", Biomicrofluidics, 13, pp.054106~ (2019)
290. Loyau S, "Microfluidic modeling of thrombolysis : effect of antiplatelet and anticoagulant agents on tPA(tissue-type plasminogen activator)-induced fibrinolysis", Arterioscler Thromb Vasc Biol, 38, pp.2626~2637 (2018)
291. Costa PF, "Mimicking arterial thrombosis in a 3D-printed microfluidic in vitro vascular model based on computed tomography angiography data", Lab Chip, 17, pp.2785~2792 (2017)
292. van Duinen V, "Perfused 3D angiogenic sprouting in a high-throughput in vitro platform", Angiogenesis, 22, pp.157~165 (2019)
293. Jiwon Kim, "Short‐Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State", Annals of Neurology, 89(3), pp.444~458 (2021), Wiley[DOI]

관련 논문AI추천